-
-
-
-
-
-
-
Krystal Biotech receives FDA RMAT designation for KB707 lung cancer therapy
-
-
-
-
-
-
-
Johnson & Johnson reports early pilot study results for atrial fibrillation device
-
-
-
-
-
-
-
FDA removes usage limitations for Kite's Yescarta in brain lymphoma treatment
-
-
-
-
-
-
-
FDA grants priority review for Pfizer's HYMPAVZI in hemophilia patients
-
-
-
-
-
-
-
Mirum receives Health Canada approval for LIVMARLI tablet formulation
-
-
-
-
-
-
-
QIMC receives second drilling approval for Nova Scotia hydrogen project
-
-
-
-
-
-
-
SAREPTA gets approval to test Huntington's disease treatment in humans
-
73,951 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.

